Login
Need to Register?   Forgot Password?
You need to upgrade your Flash Player to view this content.



What's New?
  • Your opinion requested!


  • Clinical Insights® in Lipid Management Issue 12 now available
    Co-Editor and CCMD Education Council Member Peter Libby, MD, comments on results from the ENHANCE trial. Also featured: lipoprotein(a) levels are continuously associated with future CHD risk; very high levels of HDL-C and very large HDL particle size are associated with increased CV risk.
  • New CME-certified case study now live!
    CCMD Faculty Member James M. McKenney, PharmD, presents a case exploring the assessment and management of a patient with atherogenic dyslipidemia. Upon completion of the evaluation form, you'll earn 0.75 AMA PRA Category 1 Credit™ instantly!
  • CMDManagement™ Summer 2008 issue now available for CME credit!
    This issue of our award-winning newsletter explores the benefits of lipid-lowering therapies beyond LDL-C lowering. Also featured: a case study from CCMD Faculty Member Peter H. Jones, MD, exploring the management of a patient with evidence of subclinical atherosclerosis, and a patient handout focusing on prevention of coronary artery disease.
  • The latest in clinical literature
    New selections: The association between physical activity and cardiovascular event risk, featuring expert commentary from CCMD Faculty Member Ezra A. Amsterdam, MD; baseline characteristics of participants in JUPITER; impact of the metabolic syndrome on macro- and microvascular outcomes in type 2 diabetes in UKPDS; and much more.
  • New slides in the Dynamic Slide Library
    Visit our expanding library to view and download 11 new slides focusing on data from recent clinical trials, including ASTEROID, JUPITER, METEOR, ENHANCE, and SEACOAST.
  • New drug treatment table for hypertension
    Read and download this new table that organizes various pharmacologic treatment options for hypertension, including diuretics, adrenergic inhibitors, alpha- and beta-blockers, direct vasodilators, calcium channel blockers, ACE inhibitors, ARBs, and more.
  • FDA Alert: Simvastatin With Amiodarone Increases Risk of Rhabdomyolysis
    On August 8 ,2008, the FDA released a warning regarding reports of increased rhabdomyolysis risk from concomitant use of simvastatin greater than 20 mg qd and amiodarone, an arrhythmia treatment for controlling life-threatening recurrent ventricular arrhythmias. In its alert, the FDA noted that all statins have a potential risk of rhabdomyolysis, whether or not they are administered with amiodarone, but the risk is more prominent when used with the arrhythmia agent.
    • Slides of the Month
     
    slide
    ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses
    A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary At...
    slide
    METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint
    The Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) study ...
    slide
    ENHANCE: Combined Statin Therapy—Primary Outcome
    The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis R...
    slide
    ENHANCE: Combined Statin Therapy—Effects on Lipoproteins
    The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENH...
    slide
    SEACOAST: Combination Therapy for Increased Non–HDL-C
    Primary Endpoint
    This 24-week study, part of the Safety and Efficacy of A COmbination of niAcin ER and Si...
    slide
    Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (1 of 2)
    This post-hoc analysis of four randomized, controlled trials investigated the relationship bet...
    slide
    Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (2 of 2)
    This post-hoc analysis of 4 randomized, controlled trials investigated the relationship betwee...
    slide
    METEOR: Effects of Statin Therapy on Low-Risk Patients—
    Secondary Endpoints
    The Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) study ...
    slide
    JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
    Rationale for the Justification for the Use of statins in Primary prevention: an Interve...
    slide
    JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
    The Justification for the Use of statins in Primary prevention: an Intervention Trial Ev...
    In the News
    New EkoSonic? Endovascular System With Rapid Pulse? Modulation Technology 4 Times Faster Than Conventional Catheter-Directed Thrombolysis
    Sep 05, 2008 -- EKOS Corporation announced the launch of the EkoSonic? Endovascular System (EkoSonic ES) with Rapid Pulse Modulation (RPM) for the dissolution of vascular blood clots. EkoSonic ES is the only endovascular system that can deliver microsonic energy and thrombolytic drugs simultaneously, providing a safer, faster and more complete way to remove clots by accelerating dissolution. The EkoSonic ES recently received FDA clearance.
    Low Birth Weight Children Should Have Their Blood Pressure Checked
    Sep 05, 2008 -- Blood pressure in low-birth-weight children younger than 3 years of age not only can be measured but should be, researchers at UT Southwestern Medical Center have found. The findings appear in the September issue of Pediatrics.
    Copyright 2007 Medical News Today